Physician profile
Ramin Ipakchi
NPI 1912080334
$8,733.71
in general payments reported to CMS, 2019-2025
22 companies · $854 in 2025
The $854 reported for 2025 was more than what 76% of Otolaryngology providers received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,916 · 2020: $39.81 · 2021: $274 · 2022: $456 · 2023: $703 · 2024: $491 · 2025: $854.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,948 · Education: $99.26.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,948.45 |
| Education | $99.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Optinose US, INC. | $5,895.33 | 2019-2025 | |
| Genzyme Corporation | $599.04 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $366.60 | 2023-2025 | Dupixent |
| Inspire Medical Systems, INC. | $319.60 | 2019 | |
| Medtronic, INC. | $251.68 | 2023-2025 | Pteye Parathyroid Detection System, Bizact |
| Glaxosmithkline, LLC. | $243.41 | 2021-2025 | Nucala |
| Aerin Medical INC. | $230.08 | 2019-2025 | |
| Acclarent, INC | $151.38 | 2019-2023 | Relieva Spinplus |
| Alk-Abello, INC | $137.43 | 2019-2024 | Alternaria Tenuis, Timothy, Standardized, Standardized Mite D. Farinae |
| Integra Lifesciences Corporation | $133.28 | 2024-2025 | Inspira Air, Acclarent Aera, Trudi Probe |
| Intersect Ent, INC. | $100.00 | 2019 | |
| Merck Sharp & Dohme LLC | $51.17 | 2023-2025 | Keytruda |
| Neurent Medical Limited | $48.20 | 2024 | Neuromark Device, Neuromark Radiofrequency Console |
| Ars Pharmaceuticals Operations, INC. | $42.40 | 2025 | Neffy |
| Stryker Corporation | $40.80 | 2022-2024 | Audion Et Dilation System, Scopis Ent |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kaleo, INC. | $30.32 | 2019 | |
| Phadia US INC. | $18.86 | 2019 | |
| Lilly USA, LLC | $18.53 | 2025 | Zepbound |
| Resmed Corp | $16.12 | 2019 | |
| Vanda Pharmaceuticals INC. | $14.13 | 2021 | |
| Hikma Pharmaceuticals USA | $13.27 | 2023 | Ryaltris |
| Galderma Laboratories, L.P. | $12.08 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ramin Ipakchi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.